Asia-pacific Immunoglobulin Market Forecast 2022-2030

The Asia-Pacific immunoglobulin market is estimated to grow with a CAGR of 7.20% during the forecast period of 2022 to 2030. The market growth of the region is fuelled by the launch of advanced and innovative immunoglobulin products, the rise in the geriatric population, and the increasing incidence of various disease types.

MARKET INSIGHTS

The Asia-Pacific immunoglobulin market growth assessment entails the evaluation of China, South Korea, Indonesia, Vietnam, Japan, India, Australia, Thailand, and Rest of Asia-Pacific. Key players are engaged in the launch and development of innovative immunoglobulin products in India. For example, Cipla, in 2021, launched Roche's COVID antibody cocktail (Imdevimab and Casirivimab) in the country. It is administered for treating moderate to mild COVID-19 in adults and pediatric patients. Casirivimab, as well as Imdevimab, entail human immunoglobulin G-1 (IgG1) monoclonal antibodies produced by recombinant DNA technology in laboratories.

Conversely, there has been a substantial rise in healthcare expenditure in Indonesia. As a result, patients experiencing various types of immunodeficiency diseases and other rare conditions gain fast and easy access to technologically advanced and novel healthcare facilities. Moreover, this factor not only helps in the effective diagnosis but also facilitates improved treatment for numerous disease types. Therefore, these factors are anticipated to propel the market growth in the Asia-Pacific during the forecast period.

COMPETITIVE INSIGHTS

Prominent companies operating in the market include: Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited, Shanghai RAAS Blood Products Co Ltd, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 46417

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. GROWTH IN GERIATRIC POPULATION
- 3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
- 3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COST OF THERAPY
- 3.2.2. HIGH RISK OF SIDE EFFECTS

4. KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
- 4.6.1. SOURCE
- 4.6.2. APPLICATION
- 4.6.3. EPITOPE
- 4.6.4. VALIDATION
4.7. REGULATORY FRAMEWORK

5. MARKET BY PRODUCT

5.1. IGG
5.2. IGA
5.3. IGM
5.4. IGE
5.5. IGD

6. MARKET BY MODE OF DELIVERY

6.1. INTRAVENOUS IMMUNOGLOBULIN
6.2. SUBCUTANEOUS IMMUNOGLOBULIN
6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7. MARKET BY APPLICATION

7.1. HYPOGAMMA GLOBULINEMIA
7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
7.3. PRIMARY IMMUNODEFICIENCY DISEASES
7.4. MYASTHENIA GRAVIS
7.5. MULTIFOCAL MOTOR NEUROPATHY
7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
7.7. INFLAMMATORY MYOPATHIES
7.8. SPECIFIC ANTIBODY DEFICIENCY
7.9. GUILLAIN-BARRE SYNDROME
7.10. OTHER APPLICATIONS

8. MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACY
8.2. SPECIALTY PHARMACY
8.3. OTHER DISTRIBUTION CHANNELS

9. MARKET BY END-USER

9.1. HOSPITALS & CLINICS
9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

10.1. ASIA-PACIFIC
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. KEY GROWTH ENABLERS
- 10.1.3. KEY CHALLENGES
- 10.1.4. KEY PLAYERS
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. CHINA
  - 10.1.5.2. JAPAN
  - 10.1.5.3. INDIA
  - 10.1.5.4. SOUTH KOREA
  - 10.1.5.5. INDONESIA
  - 10.1.5.6. THAILAND
  - 10.1.5.7. VIETNAM
  - 10.1.5.8. AUSTRALIA
  - 10.1.5.9. REST OF ASIA-PACIFIC

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
- 11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
11.2. COMPANY PROFILES
- 11.2.1. ADMA BIOLOGICS
- 11.2.2. BIO PRODUCTS LABORATORY
- 11.2.3. BIOTEST AG
- 11.2.4. CHINA BIOLOGIC PRODUCTS INC
- 11.2.5. CSL BEHRING
- 11.2.6. GRIFOLS SA
- 11.2.7. KAMADA LTD
- 11.2.8. KEDRION BIOPHARMA
- 11.2.9. LFB GROUP
- 11.2.10. OCTAPHARMA AG
- 11.2.11. PFIZER INC
- 11.2.12. SANQUIN PLASMA PRODUCTS BV
- 11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD
- 11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
- 11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED